# Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2

> **NCT00425035** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 115 (—)

## Conditions studied

- Advanced Renal Cell Carcinoma

## Interventions

- **DRUG:** Panitumumab (ABX-EGF)

## Key facts

- **NCT ID:** NCT00425035
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 115 (—)
- **Last updated:** 2013-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00425035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00425035, "Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00425035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*